However, with the increasing use of comprehensive panels, rare molecular findings have come to light.1MET gene aberrations are now well described, with MET exon 14 skipping being the most common, occurring in 2%-4% of NSCLC and predicting sensitivity to MET inhibitors such as crizotinib, capmatinib, tepotinib, and savolitinib. This evidence concerns the gene MET and non-small cell lung carcinoma.